Melinta therapeutics, inc. /new/ (MLNT)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenue
Total revenue

96,430

33,864

0

-

-

-

-

-

-

Contract research

-

-

-

-

9,609

3,477

-

-

-

License

-

-

-

-

4,339

4,335

-

-

-

Supply

-

-

-

-

1,268

-

-

-

-

Total revenue

-

-

-

-

15,216

7,812

-

-

0

Operating expenses:
Cost of goods sold

41,057

0

0

-

-

-

-

-

-

Research and development

55,409

49,475

49,791

62,788

62,539

41,299

16,869

16,871

15,474

Goodwill impairment

25,088

0

0

-

-

-

-

-

-

Selling, general and administrative

133,312

63,325

19,410

14,159

-

-

-

-

-

General and administrative

-

-

-

-

12,077

9,433

6,068

3,707

3,198

Total operating expenses

254,866

112,800

69,201

76,947

74,616

50,733

22,937

20,579

18,672

Loss from operations

-158,436

-78,936

-69,201

-76,947

-59,400

-42,920

-22,937

-20,579

-18,672

Other income (expense):
Interest income

730

155

30

31

134

17

107

81

4

Interest expense

43,179

3,608

3,390

3,160

2,383

2,132

1,396

722

1,495

Interest Expense, Debt

0

4,016

1,016

-

-

-

-

-

-

Change in fair value of tranche assets and liabilities

0

0

-1,313

-2,727

-

-

-

-

-

Fair Value Adjustment of Warrants

-33,226

-335

-781

-42

-

-

-

-

-

Gain (Loss) on Extinguishment of Debt

-2,595

-607

0

-

-

-

-

-

-

Grant income

-5,828

0

0

3,978

-

-

-

-

-

Other income and expense

1,904

98

177

107

-

-

-

-

-

Gain (Loss) on Contract Termination

5,330

0

0

-

-

-

-

-

-

Business Combination, Bargain Purchase, Gain Recognized, Amount

0

27,663

0

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

488

Other income (expense), net

1,244

20,020

-4,731

-1,729

-2,249

-2,114

-1,289

-641

-1,002

Net Income (Loss) Attributable to Parent

-157,192

-58,916

-73,932

-78,676

-61,649

-45,034

-24,226

-21,220

-

Accretion of convertible preferred stock dividends

0

19,259

21,117

-

-

-

-

-

-

Accretion of convertible preferred stock dividends

-

-

-

16,248

-

-

-

-

-

Accretion of redeemable convertible preferred shares

-

-

-

-

-

-

313

-

-

Net loss and comprehensive loss

-

-

-

-

-

-

-

-

-19,674

Accretion of redeemable convertible preferred shares

-

-

-

-

-

-

-

3,763

3,238

Net loss available to common shareholders

-157,192

-78,175

-95,049

-94,924

-

-

-24,540

-24,983

-22,913

Basic and diluted net loss per share (in usd per share)

-17.12

-109.28

-20,600.13

-26,171.49

-1.81

-1.53

-1.23

-47.53

-46.60

Basic and diluted weighted average shares outstanding (in shares)

9,181

715

4

3

34,130

29,449

19,882

525

491

Product sales, net
Total revenue

46,580

0

0

-

-

-

-

-

-

Contract research
Total revenue

11,677

13,959

0

-

-

-

-

-

-

License
Total revenue

38,173

19,905

0

-

-

-

-

-

-